Full metadata record

DC FieldValueLanguage
dc.contributor.author도준영ko
dc.contributor.authorPhilip K.T. Li[Philip K.T. Li]ko
dc.contributor.authorBruce F. Culleton[Bruce F. Culleton]ko
dc.contributor.authorAmaury Ariza[Amaury Ariza]ko
dc.contributor.authorDavid W. Johnson[David W. Johnson]ko
dc.contributor.authorMauricio Sanabria[Mauricio Sanabria]ko
dc.contributor.authorTy R. Shockley[Ty R. Shockley]ko
dc.contributor.authorKen Story[Ken Story]ko
dc.contributor.authorAndrey Vatazin[Andrey Vatazin]ko
dc.contributor.authorMauro Verrelli[Mauro Verrelli]ko
dc.contributor.authorAlex W. Yu[Alex W. Yu]ko
dc.contributor.authorJoanne M. Bargman[Joanne M. Bargman]ko
dc.date.accessioned2015-12-17T02:30:39Z-
dc.date.available2015-12-17T02:30:39Z-
dc.date.created2015-11-13-
dc.date.issued201311-
dc.identifier.citationJOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, v.24, no.11, pp.1889 - 1900-
dc.identifier.issn1046-6673-
dc.identifier.urihttp://hdl.handle.net/YU.REPOSITORY/28460-
dc.identifier.urihttp://dx.doi.org/10.1681/ASN.2012100987-
dc.description.abstractGlucose-containing peritoneal dialysis solutions may exacerbate metabolic abnormalities and increase cardiovascular risk in diabetic patients. Here, we examined whether a low-glucose regimen improves metabolic control in diabetic patients undergoing peritoneal dialysis. Eligible patients were randomly assigned in a 1:1 manner to the control group (dextrose solutions only) or to the low-glucose intervention group (IMPENDIA trial: combination of dextrose-based solution, icodextrin and amino acids; EDEN trial: a different dextrose-based solution, icodextrin and amino acids) and followed for 6 months. Combining both studies, 251 patients were allocated to control (n=127) or intervention (n=124) across 11 countries. The primary endpoint was change in glycated hemoglobin from baseline. Mean glycated hemoglobin at baseline was similar in both groups. In the intention-to-treat population, the mean glycated hemoglobin profile improved in the intervention group but remained unchanged in the control group (0.5% difference between groups; 95% confidence interval, 0.1% to 0.8%; P=0.006). Serum triglyceride, very-low-density lipoprotein, and apolipoprotein B levels also improved in the intervention group. Deaths and serious adverse events, including several related to extracellular fluid volume expansion, increased in the intervention group, however. These data suggest that a low-glucose dialysis regimen improves metabolic indices in diabetic patients receiving peritoneal dialysis but may be associated with an increased risk of extracellular fluid volume expansion. Thus, use of glucose-sparing regimens in peritoneal dialysis patients should be accompanied by close monitoring of fluid volume status.-
dc.language영어-
dc.publisherAMER SOC NEPHROLOGY-
dc.subjectPREDIALYSIS GLYCEMIC CONTROL-
dc.subjectCHRONIC KIDNEY-DISEASE-
dc.subjectMAINTENANCE HEMODIALYSIS-
dc.subjectICODEXTRIN IMPROVES-
dc.subjectINSULIN-RESISTANCE-
dc.subjectMETABOLIC SYNDROME-
dc.subjectGLYCATED ALBUMIN-
dc.subjectFLUID MANAGEMENT-
dc.subjectCAPD PATIENTS-
dc.subjectMORTALITY-
dc.titleRandomized, Controlled Trial of Glucose-Sparing Peritoneal Dialysis in Diabetic Patients-
dc.typeArticle-
dc.identifier.wosid000329911300020-
dc.identifier.scopusid2-s2.0-84887039338-
Appears in Collections:
의과대학 > 내과학교실 > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE